Phillip Chan Buys 3,774 Shares of Cytosorbents (NASDAQ:CTSO) Stock

Cytosorbents Corporation (NASDAQ:CTSO) CEO Phillip Chan bought 3,774 shares of the company’s stock in a transaction that occurred on Tuesday, September 15th. The shares were bought at an average price of $6.00 per share, with a total value of $22,644.00. Following the completion of the acquisition, the chief executive officer directly owned 100,996 shares in the company, valued at $605,976. This trade represents a 3.88% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Cytosorbents Price Performance

CTSO opened at $5.76 on Friday. The company has a debt-to-equity ratio of 4.70, a current ratio of 0.66 and a quick ratio of 0.50. The stock’s 50 day simple moving average is $7.12 and its 200 day simple moving average is $9.70. The firm has a market cap of $18.14 million, a price-to-earnings ratio of -0.99 and a beta of 1.34. Cytosorbents Corporation has a 1 year low of $5.13 and a 1 year high of $20.40.

Cytosorbents (NASDAQ:CTSO) last released its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.73. Cytosorbents had a negative return on equity of 431.65% and a negative net margin of 48.94%.The firm had revenue of $9.63 million during the quarter, compared to analyst estimates of $9.38 million. As a group, analysts predict that Cytosorbents Corporation will post -4.4 earnings per share for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research note on Monday, July 6th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $107.50.

About Cytosorbents

CytoSorbents Corporation develops medical devices and blood-purification technologies designed to remove harmful substances from the bloodstream. Its proprietary technology uses porous polymer adsorbent beads that can capture and reduce levels of inflammatory mediators, drugs, toxins and other compounds without selectively removing beneficial blood components.

The company’s principal product, CytoSorb, is used in extracorporeal blood purification applications, including the management of cytokine storms and other inflammatory conditions associated with critical illness, cardiac surgery, trauma and sepsis.